NIDA approves UCLA Phase 2 study of MediciNova MN-166
The fund is intended for atistically powered Phase 2 outpatient study in methamphetamine addicts, for which MediciNova will provide drug supply and regulatory support. UCLA Departments of Family
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
The two-year grant worth $300,000 will support Soligenix’s multicenter, open-label, pilot study enrolling patients that have received allogeneic hematopoietic cell transplantation at least 100 days earlier, have documented